FindTrial
Sign In

Development of Medication Adherence tool for select NCDs in Indian population

Development and validation of a novel tool to measure medication adherence for select NCDs in the Indian population - An Exploratory sequential mixed method multicentric study - JIMAT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/059643
Enrollment
1200
Registered
2023-11-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery Health Condition 2: J449- Chronic obstructive pulmonary disease, unspecified Health Condition 3: I10- Essential (primary) hypertension Health Condition 4: J452- Mild intermittent asthma Health Condition 5: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Select NCD patients (T2 Diabetes on OHA, hypertension, CAD, COPD/Bronchial Asthma) on drug treatment for at least 1 year Age above 18 years

Exclusion criteria

Exclusion criteria: Presence of any cognitive and psychological disorders and debilitating illness that interfere with the responsiveness

Design outcomes

Primary

MeasureTime frame
Primary Endpoints Psychometric properties such as Sensitivity, specificity, CVI, CVR, Cronbach’s alpha & factor structure of the tool ROC curve for determining cut off score between adherent & non-adherent participants Secondary Endpoints Qualitative study for Determinants of medication adherence from provider Doctors, pharmacist, nurses, programme officer) & end user perspectives Cross sectional study for Prevalence estimates of adherence for the conditions studied Timepoint: Qualitative study starts at eighth month & last for six months cognitive piloting starts at sixteenth month and last for 2 months survey administration for scale development starts at eighteenth month and last for 2 months cross sectional study starts at 24 months and last for seven months—

Secondary

MeasureTime frame
Secondary Endpoints Qualitative study for Determinants of medication adherence from provider Doctors, pharmacist, nurses, programme officer) & end user perspectives Cross sectional study for Prevalence estimates of adherence for the conditions studied Timepoint: Qualitative study starts at eighth month & last for six months cross sectional study starts at 24 months and last for seven months—

Countries

India

Contacts

Public ContactDr Joe Thomas

Jubilee Mission Medical College and Research Institute

covidjmmcri@gmail.com9447960010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026